• Insilico Medicine granted 108,423 restricted share units to three employees on October 29, 2026, under its Post-IPO RSU Scheme.
• Special awards totaling 69,540 RSUs for two employees vest in eighths quarterly starting October 30, 2026.
• One employee’s 38,883 RSUs vest two-thirds on their second employment anniversary, no earlier than 12 months post-grant, then one-twelfth quarterly thereafter.
• Vesting requires recipients to meet or exceed applicable annual performance review criteria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12388271), on October 29, 2026, and is solely responsible for the information contained therein.